Orkambi OK'd; Vertex prices new CF drug at $259k
This article was originally published in Scrip
The FDA's 2 July approval of Vertex Pharmaceuticals' new cystic fibrosis drug Orkambi came as little surprise, with everyone on Wall Street anticipating the agency would make its move ahead of the 4 July US Independence Day holiday – in which federal offices are closed on 3 July – and the 5 July Prescription Drug User Fee Act action date.
You may also be interested in...
With a second Phase III failure in nonsense mutation CF, the New Jersey biotech ends development of ataluren for CF, but continues with the drug in three smaller indications.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.